Gen9 Awarded Four U.S. Patents For Innovation In Synthetic Biology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gen9, a pioneer in DNA synthesis and assembly technology, today announced the issuance of four new U.S. patents in the fourth quarter of 2015. The awarded patents further strengthen Gen9’s already extensive intellectual property portfolio to more than 100 patents and patents pending.

“Methods for screening proteins using nucleic acid encoded chemical libraries.”

The newly issued patents are U.S. Patent Nos. 9,217,144, “Assembly of high fidelity polynucleotides”; 9,216,414, “Microfluidic devices and methods for gene synthesis”; 9,187,777, “Methods and devices for in situ DNA synthesis”; and 9,150,853, “Methods for screening proteins using nucleic acid encoded chemical libraries.”

These patents are directed to a range of gene synthesis and synthetic biology technologies, including, among other things, microfluidic systems comprising surface-capture spots configured for gene assembly in a defined order, methods for gene assembly in small volumes of solution on a support, methods for support-bound DNA synthesis, and methods for screening a protein library for expression of a protein having a desired activity.

“These new patents reflect our continued commitment to innovation in the high-throughput manufacture of synthetic DNA. Genes are the foundation of discoveries being made by our customers, and we are uniquely positioned to meet their needs, now and in the future,” said Kevin Munnelly, President and CEO of Gen9. “Additionally, many scientists are engineering proteins for useful purposes, so we see shortening the cycle time for improved protein expression as incredibly important for green chemical production, improved therapeutics and many other critical applications.”

For more information on Gen9, please visit

About Gen9

Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at

Nat Connors
617-250-8433 x 1048
Chempetitive Group for Gen9
Rachel Wallace

Back to news